Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
KUAISHOU-W
01024
5
JD HEALTH
06618
| (FY)Jan 31, 2025 | (Q4)Jan 31, 2025 | (Q3)Oct 31, 2024 | (Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | (Q1)Apr 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -35.81%751 | 100.34%100 | 159 | 242 | 250 | 1.17K | -29K | 0 | 0 | 0 |
| Operating revenue | -35.81%751 | 100.34%100 | --159 | --242 | --250 | --1.17K | ---29K | --0 | --0 | --0 |
| Cost of revenue | 5.38K | 23.64K | 5.73K | 0 | 0 | |||||
| Gross profit | -5.22K | -23.4K | -5.48K | 0 | 0 | |||||
| Operating expense | -60.66%1.01M | -134.55%-277.32K | 167.85K | 477.8K | 639.47K | 2.56M | 802.71K | 0 | 780.19K | 350.82%780.19K |
| Selling and administrative expenses | -50.06%775.16K | -179.56%-346.07K | --126.39K | --415.84K | --579K | --1.55M | --435K | --0 | --0 | ---- |
| -Selling and marketing expense | -37.01%63.03K | -59.56%6.24K | --10.91K | --22.94K | --22.94K | --100.07K | --15.43K | --0 | --0 | ---- |
| -General and administrative expense | -50.95%712.13K | -183.97%-352.31K | --115.47K | --392.9K | --556.06K | --1.45M | --419.57K | ---- | ---- | ---- |
| Research and development costs | 28.90%195.65K | -6.18%61.03K | --31.25K | --51.08K | --52.28K | --151.79K | --65.05K | --0 | --780.19K | 350.82%780.19K |
| Depreciation amortization depletion | --0 | --0 | --0 | --0 | ---- | --833.33K | --277.78K | ---- | --0 | ---- |
| -Depreciation and amortization | --0 | --0 | --0 | --0 | ---- | --833.33K | --277.78K | ---- | --0 | ---- |
| Other operating expenses | 48.66%36.99K | --7.72K | --10.21K | --10.88K | --8.19K | --24.88K | ---- | ---- | ---- | ---- |
| Operating profit | 60.68%-1.01M | 137.53%312.17K | -173.07K | -501.2K | -644.94K | -2.56M | -831.71K | 0 | -780.19K | -350.82%-780.19K |
| Net non-operating interest income (expenses) | 0 | 19.78K | -3.39K | -16.39K | 38.14K | |||||
| Non-operating interest income | --0 | ---- | ---- | ---- | ---- | --38.14K | ---- | ---- | ---- | ---- |
| Non-operating interest expense | ---- | ---- | --3.39K | --16.39K | ---- | ---- | ---- | ---- | ---- | ---- |
| Other net income (expenses) | 99.43%-23.59K | 99.55%-18.53K | 4.21K | -4.63K | -4.64K | -4.17M | -4.11M | |||
| Gain on sale of security | -3,117.74%-23.59K | -133.79%-18.53K | --4.21K | ---4.63K | ---4.64K | ---733 | --54.83K | ---- | ---- | ---- |
| Special income (charges) | --0 | ---- | ---- | ---- | ---- | ---4.17M | ---- | ---- | ---- | ---- |
| -Less:Impairment of capital assets | --0 | ---- | ---- | ---- | ---- | --4.17M | ---- | ---- | ---- | ---- |
| Income before tax | 84.59%-1.03M | 106.39%313.42K | -172.25K | -522.22K | -649.59K | -6.69M | -4.91M | 0 | -780.19K | -350.82%-780.19K |
| Income tax | 0 | |||||||||
| Earnings from equity interest net of tax | ||||||||||
| Net income | 84.59%-1.03M | 106.39%313.42K | -172.25K | -522.22K | -649.59K | -6.69M | -4.91M | 0 | -780.19K | -350.82%-780.19K |
| Net income continuous operations | 84.59%-1.03M | 106.39%313.42K | ---172.25K | ---522.22K | ---649.59K | ---6.69M | ---4.91M | --0 | ---780.19K | -350.82%-780.19K |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 84.59%-1.03M | 106.39%313.42K | -172.25K | -522.22K | -649.59K | -6.69M | -4.91M | 0 | -780.19K | -350.82%-780.19K |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 84.59%-1.03M | 106.39%313.42K | -172.25K | -522.22K | -649.59K | -6.69M | -4.91M | 0 | -780.19K | -350.82%-780.19K |
| Diluted earnings per share | 91.43%-0.03 | 105.91%0.01 | -0.01 | -0.02 | -0.03 | -0.35 | -0.1693 | 0 | -0.0272 | -350.84%-0.0272 |
| Basic earnings per share | 91.43%-0.03 | 105.91%0.01 | -0.01 | -0.02 | -0.03 | -0.35 | -0.1693 | 0 | -0.0272 | -350.84%-0.0272 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.